Diabetic Retinopathy- Market Insight, Epidemiology and Market Forecast - 2027

SKU ID : DEL-DIMI0007

Publishing Date : 01-Jan-2018

No. of pages : 100

PRICE
6250
18750


  • DelveInsight's "Diabetic Retinopathy - Market Insight, Epidemiology and Market Forecast - 2027" report provides a detailed analysis of the Diabetic Retinopathy epidemiology and market outlook for the 7MM.

    Markets Covered
    • United States
    • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
    • Japan

    Study Period: 2016-2027

    Diabetic Retinopathy Understanding and Treatment Algorithm
    The market report provides the overview of the Diabetic Retinopathy by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.

    Diabetic Retinopathy Epidemiology
    The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2018 to 2027 segmented by seven major markets, enabling to understand the potential of the Diabetic Retinopathy in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.

    Diabetic Retinopathy Product Profiles & Analysis
    The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.

    Diabetic Retinopathy Market Outlook
    The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Diabetic Retinopathy market.

    Diabetic Retinopathy Market Share by Therapies
    This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2027. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.

    Diabetic Retinopathy Report Insights
    • Patient Population in Diabetic Retinopathy
    • Therapeutic Approaches in Diabetic Retinopathy
    • Diabetic Retinopathy Pipeline Analysis
    • Diabetic Retinopathy Market Size and Trends
    • Diabetic Retinopathy Market Opportunities
    • Impact of upcoming Therapies in Diabetic Retinopathy

    Diabetic Retinopathy Report Key Strengths
    • 10 Year Forecast
    • 7MM Coverage
    • Epidemiology Segmentation
    • Drugs Uptake
    • Highly Analyzed Market
    • Key Cross Competition

    Diabetic Retinopathy Report Assessment
    • Current Treatment Practices in Diabetic Retinopathy
    • Unmet Needs in Diabetic Retinopathy
    • Market Attractiveness
    • Market Drivers and Barriers

    Key Benefits
    • The report will help to develop Business Strategies by understanding the trends shaping and driving the Diabetic Retinopathy market
    • Organize sales and marketing efforts by identifying the best opportunities for Diabetic Retinopathy market
    • To understand the future market competition in the Diabetic Retinopathy market.

    Detailed TOC of Diabetic Retinopathy- Market Insight, Epidemiology and Market Forecast - 2027

    1. Report Introduction
    2. Diabetic Retinopathy Market Overview at a Glance
    2.1. Market Share Distribution of Diabetic Retinopathy in 2017
    2.2. Market Share Distribution of Diabetic Retinopathy in 2027
    3. Disease Background and Overview: Diabetic Retinopathy
    3.1. Introduction
    3.2. Symptoms
    3.3. Etiology
    3.4. Risk Factors
    3.5. Pathophysiology
    3.6. Diagnosis
    3.7. Treatment
    4. Epidemiology and Patient Population
    4.1. Key Findings
    4.2. Total Prevalent/ Incident Patient Population of Diabetic Retinopathy in 7MM
    4.3. Total Prevalent Patient Population of Diabetic Retinopathy in 7MM – By Countries
    5. Epidemiology of Diabetic Retinopathy by Countries
    5.1. United States
    5.1.1. Assumptions and Rationale
    5.1.2. Prevalent/Incident Cases of the Diabetic Retinopathy
    5.1.3. Sub-Type Specific cases of the Diabetic Retinopathy *
    5.1.4. Sex- Specific Cases of the Diabetic Retinopathy*
    5.1.5. Diagnosed Cases of the Diabetic Retinopathy
    5.1.6. Treatable Cases of the Diabetic Retinopathy
    5.2. EU5
    5.3. Assumptions and Rationale
    5.4. Germany
    5.4.1. Assumptions and Rationale
    5.4.2. Prevalent/Incident Cases of the Diabetic Retinopathy
    5.4.3. Sub-Type Specific cases of the Diabetic Retinopathy*
    5.4.4. Sex- Specific Cases of the Diabetic Retinopathy*
    5.4.5. Diagnosed Cases of the Diabetic Retinopathy
    5.4.6. Treatable Cases of the Diabetic Retinopathy
    5.5. France
    5.5.1. Assumptions and Rationale
    5.5.2. Prevalent/Incident Cases of the Diabetic Retinopathy
    5.5.3. Sub-Type Specific cases of the Diabetic Retinopathy*
    5.5.4. Sex- Specific Cases of the Diabetic Retinopathy*
    5.5.5. Diagnosed Cases of the Diabetic Retinopathy
    5.5.6. Treatable Cases of the Diabetic Retinopathy
    5.6. Italy
    5.6.1. Assumptions and Rationale
    5.6.2. Prevalent/Incident Cases of the Diabetic Retinopathy
    5.6.3. Sub-Type Specific cases of the Diabetic Retinopathy*
    5.6.4. Sex- Specific Cases of the Diabetic Retinopathy*
    5.6.5. Diagnosed Cases of the Diabetic Retinopathy
    5.6.6. Treatable Cases of the Diabetic Retinopathy
    5.7. Spain
    5.7.1. Assumptions and Rationale
    5.7.2. Prevalent/Incident Cases of the Diabetic Retinopathy
    5.7.3. Sub-Type Specific cases of the Diabetic Retinopathy*
    5.7.4. Sex- Specific Cases of the Diabetic Retinopathy*
    5.7.5. Diagnosed Cases of the Diabetic Retinopathy
    5.7.6. Treatable Cases of the Diabetic Retinopathy
    5.8. United Kingdom
    5.8.1. Assumptions and Rationale
    5.8.2. Prevalent/Incident Cases of the Diabetic Retinopathy
    5.8.3. Sub-Type Specific cases of the Diabetic Retinopathy*
    5.8.4. Sex- Specific Cases of the Diabetic Retinopathy*
    5.8.5. Diagnosed Cases of the Diabetic Retinopathy
    5.8.6. Treatable Cases of the Diabetic Retinopathy
    5.9. Japan
    5.9.1. Assumptions and Rationale
    5.9.2. Prevalent/Incident Cases of the Diabetic Retinopathy
    5.9.3. Sub-Type Specific cases of the Diabetic Retinopathy*
    5.9.4. Sex- Specific Cases of the Diabetic Retinopathy*
    5.9.5. Diagnosed Cases of the Diabetic Retinopathy
    5.9.6. Treatable Cases of the Diabetic Retinopathy
    6. Current Treatment & Medical practices
    6.1. Treatment Algorithm
    6.2. Treatment Guidelines
    7. Unmet Needs of the Diabetic Retinopathy
    8. Marketed Therapies
    8.1. Drug A: Company 1
    8.1.1. Drug Description
    8.1.2. Mechanism of Action
    8.1.3. Regulatory Milestones
    8.1.4. Advantages & Disadvantages
    8.1.5. Product Profile
    8.2. Drug B: Company 2
    8.2.1. Drug Description
    8.2.2. Mechanism of Action
    8.2.3. Regulatory Milestones
    8.2.4. Advantages & Disadvantages
    8.2.5. Product Profile
    9. Pipeline Therapies – At a glance
    10. Key Cross Competition
    11. Emerging Therapies for Diabetic Retinopathy
    11.1. Drug C: Company 3
    11.1.1. Drug Description
    11.1.2. Clinical Trials Details
    11.1.3. Safety and Efficacy Profile
    11.1.4. Advantages & Disadvantages
    11.1.5. Pipeline Development Activities
    11.1.6. Product Profile
    11.2. Drug D: Company 4
    11.2.1. Drug Description
    11.2.2. Clinical Trials Details
    11.2.3. Safety and Efficacy Profile
    11.2.4. Advantages & Disadvantages
    11.2.5. Pipeline Development Activities
    11.2.6. Product Profile
    12. Diabetic Retinopathy: 7MM Market Analysis
    12.1. 7MM Market Size of Diabetic Retinopathy
    12.2. 7MM Percentage Share of drugs marketed for Diabetic Retinopathy
    12.3. 7MM Market Sales of Diabetic Retinopathy by Products
    13. Diabetic Retinopathy: Country-Wise Market Analysis
    13.1. United States
    13.1.1. Market Size of Diabetic Retinopathy in United States
    13.1.2. Percentage Share of drugs marketed for Diabetic Retinopathy in United States
    13.1.3. Market Sales of Diabetic Retinopathy by Products in United States
    13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2. EU-5
    13.2.1. Germany
    13.2.1.1. Market Size of Diabetic Retinopathy in Germany
    13.2.1.2. Percentage Share of drugs marketed for Diabetic Retinopathy in Germany
    13.2.1.3. Market Sales of Diabetic Retinopathy by Products in Germany
    13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.2. France
    13.2.2.1. Market Size of Diabetic Retinopathy in France
    13.2.2.2. Percentage Share of drugs marketed for Diabetic Retinopathy in France
    13.2.2.3. Market Sales of Diabetic Retinopathy by Products in France
    13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.3. Italy
    13.2.3.1. Market Size of Diabetic Retinopathy in Italy
    13.2.3.2. Percentage Share of drugs marketed for Diabetic Retinopathy in Italy
    13.2.3.3. Market Sales of Diabetic Retinopathy by Products in Italy
    13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.4. Spain
    13.2.4.1. Market Size of Diabetic Retinopathy in Spain
    13.2.4.2. Percentage Share of drugs marketed for Diabetic Retinopathy in Spain
    13.2.4.3. Market Sales of Diabetic Retinopathy by Products in Spain
    13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.2.5. United Kingdom
    13.2.5.1. Market Size of Diabetic Retinopathy in United Kingdom
    13.2.5.2. Percentage Share of drugs marketed for Diabetic Retinopathy in United Kingdom
    13.2.5.3. Market Sales of Diabetic Retinopathy by Products in United Kingdom
    13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
    13.3. Japan
    13.3.1. Market Size of Diabetic Retinopathy in Japan
    13.3.2. Percentage Share of drugs marketed for Diabetic Retinopathy in Japan
    13.3.3. Market Sales of Diabetic Retinopathy by Products in Japan
    13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
    14. Market Drivers
    15. Market Barriers
    16. Appendix
    17. Report Methodology
    17.1. Sources
    18. DelveInsight Capabilities
    19. Disclaimer
    20. About DelveInsight

    *Indication Specific

    List of Figures, Tables and Charts Available in Diabetic Retinopathy- Market Insight, Epidemiology and Market Forecast - 2027

    Table 1: Total Prevalent/Incident Cases of the Diabetic Retinopathy in 7MM
    Table 2: Total Prevalent/Incident Cases of the Diabetic Retinopathy in 7MM by Countries
    Table 3: Prevalent/Incident Cases of the Diabetic Retinopathy in United States (2016-2027)
    Table 4: Sub-Type Specific cases of the Diabetic Retinopathy in United States (2016-2027)
    Table 5: Sex- Specific Cases of the Diabetic Retinopathy in United States (2016-2027)
    Table 6: Diagnosed Cases of the Diabetic Retinopathy in United States (2016-2027)
    Table 7: Treatable Cases of the Diabetic Retinopathy in United States (2016-2027)
    Table 8: Prevalent/Incident Cases of the Diabetic Retinopathy in Germany (2016-2027)
    Table 9: Sub-Type Specific cases of the Diabetic Retinopathy in Germany (2016-2027)
    Table 10: Sex- Specific Cases of the Diabetic Retinopathy in Germany (2016-2027)
    Table 11: Diagnosed Cases of the Diabetic Retinopathy in Germany (2016-2027)
    Table 12: Treatable Cases of the Diabetic Retinopathy in Germany (2016-2027)
    Table 13: Prevalent/Incident Cases of the Diabetic Retinopathy in France (2016-2027)
    Table 14: Sub-Type Specific cases of the Diabetic Retinopathy in France (2016-2027)
    Table 15: Sex- Specific Cases of the Diabetic Retinopathy in France (2016-2027)
    Table 16: Diagnosed Cases of the Diabetic Retinopathy in France (2016-2027)
    Table 17: Treatable Cases of the Diabetic Retinopathy in France (2016-2027)
    Table 18: Prevalent/Incident Cases of the Diabetic Retinopathy in Italy (2016-2027)
    Table 19: Sub-Type Specific cases of the Diabetic Retinopathy in Italy (2016-2027)
    Table 20: Sex- Specific Cases of the Diabetic Retinopathy in Italy (2016-2027)
    Table 21: Diagnosed Cases of the Diabetic Retinopathy in Italy (2016-2027)
    Table 22: Treatable Cases of the Diabetic Retinopathy in Italy (2016-2027)
    Table 23: Prevalent/Incident Cases of the Diabetic Retinopathy in Spain (2016-2027)
    Table 24: Sub-Type Specific cases of the Diabetic Retinopathy in Spain (2016-2027)
    Table 25: Sex- Specific Cases of the Diabetic Retinopathy in Spain (2016-2027)
    Table 26: Diagnosed Cases of the Diabetic Retinopathy in Spain (2016-2027)
    Table 27: Treatable Cases of the Diabetic Retinopathy in Spain (2016-2027)
    Table 28: Prevalent/Incident Cases of the Diabetic Retinopathy in UK (2016-2027)
    Table 29: Sub-Type Specific cases of the Diabetic Retinopathy in UK (2016-2027)
    Table 30: Sex- Specific Cases of the Diabetic Retinopathy in UK (2016-2027)
    Table 31: Diagnosed Cases of the Diabetic Retinopathy in UK (2016-2027)
    Table 32: Treatable Cases of the Diabetic Retinopathy in UK (2016-2027)
    Table 33: Prevalent/Incident Cases of the Diabetic Retinopathy in Japan (2016-2027)
    Table 34: Sub-Type Specific cases of the Diabetic Retinopathy in Japan (2016-2027)
    Table 35: Sex- Specific Cases of the Diabetic Retinopathy in Japan (2016-2027)
    Table 36: Diagnosed Cases of the Diabetic Retinopathy in Japan (2016-2027)
    Table 37: Treatable Cases of the Diabetic Retinopathy in Japan (2016-2027)
    Table 38: Marketed Therapies
    Table 39: Emerging Therapies
    Table 40: Key Cross Competition
    Table 41:7MM- Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Table 42:7MM- Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 43:7MM- Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 44: United States-Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Table 45: United States-Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 46: United States-Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 47: Germany-Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Table 48: Germany-Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 49: Germany-Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 50: France-Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Table 51: France-Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 52: France-Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 53: Italy-Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Table 54: Italy-Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 55: Italy-Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 56: Spain-Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Table 57: Spain-Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 58: Spain-Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 59:UK-Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Table 60:UK-Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 61:UK-Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 62: Japan-Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Table 63: Japan-Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Table 64: Japan-Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)


    Figure 1: Total Prevalent/Incident Cases of the Diabetic Retinopathy in 7MM
    Figure 2: Total Prevalent/Incident Cases of the Diabetic Retinopathy in 7MM by Countries
    Figure 3: Prevalent/Incident Cases of the Diabetic Retinopathy in United States (2016-2027)
    Figure 4: Sub-Type Specific cases of the Diabetic Retinopathy in United States (2016-2027)
    Figure 5: Sex- Specific Cases of the Diabetic Retinopathy in United States (2016-2027)
    Figure 6: Diagnosed Cases of the Diabetic Retinopathy in United States (2016-2027)
    Figure 7: Treatable Cases of the Diabetic Retinopathy in United States (2016-2027)
    Figure 8: Prevalent/Incident Cases of the Diabetic Retinopathy in Germany (2016-2027)
    Figure 9: Sub-Type Specific cases of the Diabetic Retinopathy in Germany (2016-2027)
    Figure 10: Sex- Specific Cases of the Diabetic Retinopathy in Germany (2016-2027)
    Figure 11: Diagnosed Cases of the Diabetic Retinopathy in Germany (2016-2027)
    Figure 12: Treatable Cases of the Diabetic Retinopathy in Germany (2016-2027)
    Figure 13: Prevalent/Incident Cases of the Diabetic Retinopathy in France (2016-2027)
    Figure 14: Sub-Type Specific cases of the Diabetic Retinopathy in France (2016-2027)
    Figure 15: Sex- Specific Cases of the Diabetic Retinopathy in France (2016-2027)
    Figure 16: Diagnosed Cases of the Diabetic Retinopathy in France (2016-2027)
    Figure 17: Treatable Cases of the Diabetic Retinopathy in France (2016-2027)
    Figure 18: Prevalent/Incident Cases of the Diabetic Retinopathy in Italy (2016-2027)
    Figure 19: Sub-Type Specific cases of the Diabetic Retinopathy in Italy (2016-2027)
    Figure 20: Sex- Specific Cases of the Diabetic Retinopathy in Italy (2016-2027)
    Figure 21: Diagnosed Cases of the Diabetic Retinopathy in Italy (2016-2027)
    Figure 22: Treatable Cases of the Diabetic Retinopathy in Italy (2016-2027)
    Figure 23: Prevalent/Incident Cases of the Diabetic Retinopathy in Spain (2016-2027)
    Figure 24: Sub-Type Specific cases of the Diabetic Retinopathy in Spain (2016-2027)
    Figure 25: Sex- Specific Cases of the Diabetic Retinopathy in Spain (2016-2027)
    Figure 26: Diagnosed Cases of the Diabetic Retinopathy in Spain (2016-2027)
    Figure 27: Treatable Cases of the Diabetic Retinopathy in Spain (2016-2027)
    Figure 28: Prevalent/Incident Cases of the Diabetic Retinopathy in UK (2016-2027)
    Figure 29: Sub-Type Specific cases of the Diabetic Retinopathy in UK (2016-2027)
    Figure 30: Sex- Specific Cases of the Diabetic Retinopathy in UK (2016-2027)
    Figure 31: Diagnosed Cases of the Diabetic Retinopathy in UK (2016-2027)
    Figure 32: Treatable Cases of the Diabetic Retinopathy in UK (2016-2027)
    Figure 33: Prevalent/Incident Cases of the Diabetic Retinopathy in Japan (2016-2027)
    Figure 34: Sub-Type Specific cases of the Diabetic Retinopathy in Japan (2016-2027)
    Figure 35: Sex- Specific Cases of the Diabetic Retinopathy in Japan (2016-2027)
    Figure 36: Diagnosed Cases of the Diabetic Retinopathy in Japan (2016-2027)
    Figure 37: Treatable Cases of the Diabetic Retinopathy in Japan (2016-2027)
    Figure 38: Marketed Therapies
    Figure 39: Emerging Therapies
    Figure 40: Key Cross Competition
    Figure 41:7MM- Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Figure 42:7MM- Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 43:7MM- Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 44: United States-Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Figure 45: United States-Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 46: United States-Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 47: Germany-Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Figure 48: Germany-Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 49: Germany-Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 50: France-Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Figure 51: France-Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 52: France-Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 53: Italy-Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Figure 54: Italy-Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 55: Italy-Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 56: Spain-Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Figure 57: Spain-Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 58: Spain-Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 59:UK-Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Figure 60:UK-Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 61:UK-Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 62: Japan-Market Size of Diabetic Retinopathy in USD MM (2016-2027)
    Figure 63: Japan-Market Share Diabetic Retinopathy by Therapies in USD MM (2016-2027)
    Figure 64: Japan-Market Sales of Diabetic Retinopathy by Therapies in USD MM (2016-2027)